ZA200606295B - Crystalline polymorphs of a CXC-chemokine receptor ligand - Google Patents

Info

Publication number

ZA200606295B

ZA200606295B ZA200606295A ZA200606295A ZA200606295B ZA 200606295 B ZA200606295 B ZA 200606295B ZA 200606295 A ZA200606295 A ZA 200606295A ZA 200606295 A ZA200606295 A ZA 200606295A ZA 200606295 B ZA200606295 B ZA 200606295B

Authority

ZA

South Africa

Prior art keywords

disease

compound

pain

inhibitors

group

Prior art date

2004-01-30

Links

• Espacenet
• Global Dossier
• Discuss

• 108091008928 CXC chemokine receptors Proteins 0.000 title description 5
• 102000054900 CXCR Receptors Human genes 0.000 title description 5
• 239000003446 ligand Substances 0.000 title description 5
• 238000000034 method Methods 0.000 claims description 93
• 229940126062 Compound A Drugs 0.000 claims description 86
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 86
• 201000010099 disease Diseases 0.000 claims description 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 60
• 150000001875 compounds Chemical class 0.000 claims description 57
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 55
• 208000002193 Pain Diseases 0.000 claims description 51
• 102000019034 Chemokines Human genes 0.000 claims description 44
• 108010012236 Chemokines Proteins 0.000 claims description 44
• 230000036407 pain Effects 0.000 claims description 44
• 239000000203 mixture Substances 0.000 claims description 43
• 239000002246 antineoplastic agent Substances 0.000 claims description 33
• 239000003814 drug Substances 0.000 claims description 31
• 206010028980 Neoplasm Diseases 0.000 claims description 30
• 230000001404 mediated effect Effects 0.000 claims description 26
• 150000004682 monohydrates Chemical class 0.000 claims description 26
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 26
• 239000003112 inhibitor Substances 0.000 claims description 24
• 239000005557 antagonist Substances 0.000 claims description 23
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
• 201000011510 cancer Diseases 0.000 claims description 21
• 238000004519 manufacturing process Methods 0.000 claims description 21
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 20
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
• 241000700605 Viruses Species 0.000 claims description 18
• 230000001684 chronic effect Effects 0.000 claims description 18
• 239000013078 crystal Substances 0.000 claims description 18
• 239000003960 organic solvent Substances 0.000 claims description 17
• 206010065390 Inflammatory pain Diseases 0.000 claims description 16
• 206010063837 Reperfusion injury Diseases 0.000 claims description 15
• 239000003795 chemical substances by application Substances 0.000 claims description 15
• 239000002244 precipitate Substances 0.000 claims description 15
• 201000001119 neuropathy Diseases 0.000 claims description 14
• 230000007823 neuropathy Effects 0.000 claims description 14
• 230000008569 process Effects 0.000 claims description 14
• 206010061218 Inflammation Diseases 0.000 claims description 13
• 230000001154 acute effect Effects 0.000 claims description 13
• 206010003246 arthritis Diseases 0.000 claims description 13
• 230000004054 inflammatory process Effects 0.000 claims description 13
• 208000014674 injury Diseases 0.000 claims description 13
• 150000003431 steroids Chemical class 0.000 claims description 13
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
• 206010040070 Septic Shock Diseases 0.000 claims description 12
• 238000006243 chemical reaction Methods 0.000 claims description 12
• 238000002156 mixing Methods 0.000 claims description 12
• 201000006417 multiple sclerosis Diseases 0.000 claims description 12
• -1 anti-hormones Substances 0.000 claims description 11
• 208000004296 neuralgia Diseases 0.000 claims description 11
• 208000021722 neuropathic pain Diseases 0.000 claims description 11
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 11
• 239000007787 solid Substances 0.000 claims description 11
• 208000006011 Stroke Diseases 0.000 claims description 10
• 206010047115 Vasculitis Diseases 0.000 claims description 10
• 230000002491 angiogenic effect Effects 0.000 claims description 10
• 201000008482 osteoarthritis Diseases 0.000 claims description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
• 206010021143 Hypoxia Diseases 0.000 claims description 9
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
• 201000004681 Psoriasis Diseases 0.000 claims description 9
• 239000000556 agonist Substances 0.000 claims description 9
• 239000003862 glucocorticoid Substances 0.000 claims description 9
• 229940125721 immunosuppressive agent Drugs 0.000 claims description 9
• 229960000485 methotrexate Drugs 0.000 claims description 9
• 230000003551 muscarinic effect Effects 0.000 claims description 9
• 208000023504 respiratory system disease Diseases 0.000 claims description 9
• 239000002002 slurry Substances 0.000 claims description 9
• 229940037128 systemic glucocorticoids Drugs 0.000 claims description 9
• 201000005569 Gout Diseases 0.000 claims description 8
• 208000022873 Ocular disease Diseases 0.000 claims description 8
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 8
• 208000007565 gingivitis Diseases 0.000 claims description 8
• 239000000463 material Substances 0.000 claims description 8
• 239000008194 pharmaceutical composition Substances 0.000 claims description 8
• 230000008733 trauma Effects 0.000 claims description 8
• 201000001320 Atherosclerosis Diseases 0.000 claims description 7
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
• 208000011231 Crohn disease Diseases 0.000 claims description 7
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
• 206010014561 Emphysema Diseases 0.000 claims description 7
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 7
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 7
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 7
• 208000007536 Thrombosis Diseases 0.000 claims description 7
• 206010052779 Transplant rejections Diseases 0.000 claims description 7
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
• 208000038016 acute inflammation Diseases 0.000 claims description 7
• 230000006022 acute inflammation Effects 0.000 claims description 7
• 230000033115 angiogenesis Effects 0.000 claims description 7
• 230000001363 autoimmune Effects 0.000 claims description 7
• 206010006451 bronchitis Diseases 0.000 claims description 7
• 208000006454 hepatitis Diseases 0.000 claims description 7
• 231100000283 hepatitis Toxicity 0.000 claims description 7
• 208000031225 myocardial ischemia Diseases 0.000 claims description 7
• 208000005987 polymyositis Diseases 0.000 claims description 7
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
• 201000000306 sarcoidosis Diseases 0.000 claims description 7
• 208000023275 Autoimmune disease Diseases 0.000 claims description 6
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 6
• 206010019233 Headaches Diseases 0.000 claims description 6
• 206010020751 Hypersensitivity Diseases 0.000 claims description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
• 229940124761 MMP inhibitor Drugs 0.000 claims description 6
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 6
• 208000010040 Sprains and Strains Diseases 0.000 claims description 6
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
• 108700012920 TNF Proteins 0.000 claims description 6
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 6
• 208000005298 acute pain Diseases 0.000 claims description 6
• 208000026935 allergic disease Diseases 0.000 claims description 6
• 208000006673 asthma Diseases 0.000 claims description 6
• 208000037976 chronic inflammation Diseases 0.000 claims description 6
• 229940111134 coxibs Drugs 0.000 claims description 6
• 239000003172 expectorant agent Substances 0.000 claims description 6
• 229960003776 glatiramer acetate Drugs 0.000 claims description 6
• 231100000869 headache Toxicity 0.000 claims description 6
• 238000010438 heat treatment Methods 0.000 claims description 6
• 230000009610 hypersensitivity Effects 0.000 claims description 6
• 208000002780 macular degeneration Diseases 0.000 claims description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 6
• 230000000241 respiratory effect Effects 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 238000002560 therapeutic procedure Methods 0.000 claims description 6
• 238000002054 transplantation Methods 0.000 claims description 6
• 241001529453 unidentified herpesvirus Species 0.000 claims description 6
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 208000009137 Behcet syndrome Diseases 0.000 claims description 5
• 201000006474 Brain Ischemia Diseases 0.000 claims description 5
• 206010006448 Bronchiolitis Diseases 0.000 claims description 5
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
• 206010009137 Chronic sinusitis Diseases 0.000 claims description 5
• 206010011224 Cough Diseases 0.000 claims description 5
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
• 229930105110 Cyclosporin A Natural products 0.000 claims description 5
• 108010036949 Cyclosporine Proteins 0.000 claims description 5
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
• 208000000059 Dyspnea Diseases 0.000 claims description 5
• 206010013975 Dyspnoeas Diseases 0.000 claims description 5
• 208000007465 Giant cell arteritis Diseases 0.000 claims description 5
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
• 206010058490 Hyperoxia Diseases 0.000 claims description 5
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 5
• 208000009525 Myocarditis Diseases 0.000 claims description 5
• 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 5
• 208000003251 Pruritus Diseases 0.000 claims description 5
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 5
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
• 230000001773 anti-convulsant effect Effects 0.000 claims description 5
• 230000001430 anti-depressive effect Effects 0.000 claims description 5
• 239000001961 anticonvulsive agent Substances 0.000 claims description 5
• 239000000935 antidepressant agent Substances 0.000 claims description 5
• 201000008937 atopic dermatitis Diseases 0.000 claims description 5
• 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 5
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 5
• 208000010353 central nervous system vasculitis Diseases 0.000 claims description 5
• 206010008118 cerebral infarction Diseases 0.000 claims description 5
• 208000007451 chronic bronchitis Diseases 0.000 claims description 5
• 230000006020 chronic inflammation Effects 0.000 claims description 5
• 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 5
• 229960001265 ciclosporin Drugs 0.000 claims description 5
• 229930182912 cyclosporin Natural products 0.000 claims description 5
• 230000000222 hyperoxic effect Effects 0.000 claims description 5
• 230000007954 hypoxia Effects 0.000 claims description 5
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 5
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 5
• 229960001940 sulfasalazine Drugs 0.000 claims description 5
• 206010043207 temporal arteritis Diseases 0.000 claims description 5
• 230000005951 type IV hypersensitivity Effects 0.000 claims description 5
• 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 5
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
• 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 4
• 208000015943 Coeliac disease Diseases 0.000 claims description 4
• 208000034656 Contusions Diseases 0.000 claims description 4
• 201000004624 Dermatitis Diseases 0.000 claims description 4
• 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
• 206010014824 Endotoxic shock Diseases 0.000 claims description 4
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
• 208000005232 Glossitis Diseases 0.000 claims description 4
• 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 4
• 208000004454 Hyperalgesia Diseases 0.000 claims description 4
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
• 201000009906 Meningitis Diseases 0.000 claims description 4
• 208000019695 Migraine disease Diseases 0.000 claims description 4
• 206010051606 Necrotising colitis Diseases 0.000 claims description 4
• 206010030216 Oesophagitis Diseases 0.000 claims description 4
• 208000001132 Osteoporosis Diseases 0.000 claims description 4
• 206010033645 Pancreatitis Diseases 0.000 claims description 4
• 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 4
• 206010037779 Radiculopathy Diseases 0.000 claims description 4
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 4
• 208000000924 Right ventricular hypertrophy Diseases 0.000 claims description 4
• 206010040047 Sepsis Diseases 0.000 claims description 4
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 4
• 206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
• 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
• 206010047924 Wheezing Diseases 0.000 claims description 4
• 206010000496 acne Diseases 0.000 claims description 4
• 230000010085 airway hyperresponsiveness Effects 0.000 claims description 4
• 208000002353 alcoholic hepatitis Diseases 0.000 claims description 4
• 229940100198 alkylating agent Drugs 0.000 claims description 4
• 239000002168 alkylating agent Substances 0.000 claims description 4
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
• 230000000340 anti-metabolite Effects 0.000 claims description 4
• 229940100197 antimetabolite Drugs 0.000 claims description 4
• 239000002256 antimetabolite Substances 0.000 claims description 4
• 201000009267 bronchiectasis Diseases 0.000 claims description 4
• 230000000747 cardiac effect Effects 0.000 claims description 4
• 208000025997 central nervous system neoplasm Diseases 0.000 claims description 4
• 230000009519 contusion Effects 0.000 claims description 4
• 238000000502 dialysis Methods 0.000 claims description 4
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 208000000718 duodenal ulcer Diseases 0.000 claims description 4
• 230000004064 dysfunction Effects 0.000 claims description 4
• 208000000292 ehrlichiosis Diseases 0.000 claims description 4
• 206010014599 encephalitis Diseases 0.000 claims description 4
• 208000006881 esophagitis Diseases 0.000 claims description 4
• 229940088597 hormone Drugs 0.000 claims description 4
• 239000005556 hormone Substances 0.000 claims description 4
• 208000018875 hypoxemia Diseases 0.000 claims description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
• 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
• 210000004072 lung Anatomy 0.000 claims description 4
• 206010025135 lupus erythematosus Diseases 0.000 claims description 4
• 201000004792 malaria Diseases 0.000 claims description 4
• 229960001156 mitoxantrone Drugs 0.000 claims description 4
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
• 229930014626 natural product Natural products 0.000 claims description 4
• 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 4
• 206010033072 otitis externa Diseases 0.000 claims description 4
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 4
• 201000001245 periodontitis Diseases 0.000 claims description 4
• 206010034674 peritonitis Diseases 0.000 claims description 4
• 229960004618 prednisone Drugs 0.000 claims description 4
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
• 230000036303 septic shock Effects 0.000 claims description 4
• 230000009529 traumatic brain injury Effects 0.000 claims description 4
• GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 claims description 3
• 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
• 229940124638 COX inhibitor Drugs 0.000 claims description 3
• 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
• 206010055665 Corneal neovascularisation Diseases 0.000 claims description 3
• 206010011878 Deafness Diseases 0.000 claims description 3
• 208000007882 Gastritis Diseases 0.000 claims description 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 3
• 208000019693 Lung disease Diseases 0.000 claims description 3
• 208000027530 Meniere disease Diseases 0.000 claims description 3
• 206010065673 Nephritic syndrome Diseases 0.000 claims description 3
• 108090000622 Nociceptin Proteins 0.000 claims description 3
• 206010061876 Obstruction Diseases 0.000 claims description 3
• 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
• 206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 3
• 102000011420 Phospholipase D Human genes 0.000 claims description 3
• 108090000553 Phospholipase D Proteins 0.000 claims description 3
• 206010039710 Scleroderma Diseases 0.000 claims description 3
• 229940124639 Selective inhibitor Drugs 0.000 claims description 3
• 108010039185 Tenecteplase Proteins 0.000 claims description 3
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
• 206010046851 Uveitis Diseases 0.000 claims description 3
• 208000027418 Wounds and injury Diseases 0.000 claims description 3
• 229960000446 abciximab Drugs 0.000 claims description 3
• 201000003229 acute pancreatitis Diseases 0.000 claims description 3
• 239000002597 adenosine A2 receptor agonist Substances 0.000 claims description 3
• 229960003318 alteplase Drugs 0.000 claims description 3
• 208000007502 anemia Diseases 0.000 claims description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
• 239000003146 anticoagulant agent Substances 0.000 claims description 3
• 229940127219 anticoagulant drug Drugs 0.000 claims description 3
• 229960003965 antiepileptics Drugs 0.000 claims description 3
• 239000003963 antioxidant agent Substances 0.000 claims description 3
• 229940127218 antiplatelet drug Drugs 0.000 claims description 3
• 239000003435 antirheumatic agent Substances 0.000 claims description 3
• 229960002170 azathioprine Drugs 0.000 claims description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
• 229940124630 bronchodilator Drugs 0.000 claims description 3
• 239000000168 bronchodilator agent Substances 0.000 claims description 3
• 201000000159 corneal neovascularization Diseases 0.000 claims description 3
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 3
• 230000006378 damage Effects 0.000 claims description 3
• 231100000895 deafness Toxicity 0.000 claims description 3
• 239000000850 decongestant Substances 0.000 claims description 3
• 229940124581 decongestants Drugs 0.000 claims description 3
• 230000003247 decreasing effect Effects 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 3
• 229940052760 dopamine agonists Drugs 0.000 claims description 3
• 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 3
• 239000003602 elastase inhibitor Substances 0.000 claims description 3
• 230000003419 expectorant effect Effects 0.000 claims description 3
• 229940066493 expectorants Drugs 0.000 claims description 3
• 239000000122 growth hormone Substances 0.000 claims description 3
• 208000016354 hearing loss disease Diseases 0.000 claims description 3
• 229960002897 heparin Drugs 0.000 claims description 3
• 229920000669 heparin Polymers 0.000 claims description 3
• 239000000938 histamine H1 antagonist Substances 0.000 claims description 3
• 239000003395 histamine H3 receptor antagonist Substances 0.000 claims description 3
• 239000000367 immunologic factor Substances 0.000 claims description 3
• 229960000598 infliximab Drugs 0.000 claims description 3
• 229940079322 interferon Drugs 0.000 claims description 3
• 208000028867 ischemia Diseases 0.000 claims description 3
• VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims description 3
• 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 3
• 229940066491 mucolytics Drugs 0.000 claims description 3
• 206010028417 myasthenia gravis Diseases 0.000 claims description 3
• PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 3
• 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 3
• 238000011084 recovery Methods 0.000 claims description 3
• 201000005671 spondyloarthropathy Diseases 0.000 claims description 3
• 229960000216 tenecteplase Drugs 0.000 claims description 3
• 206010047470 viral myocarditis Diseases 0.000 claims description 3
• 206010002383 Angina Pectoris Diseases 0.000 claims description 2
• 206010003011 Appendicitis Diseases 0.000 claims description 2
• 208000035143 Bacterial infection Diseases 0.000 claims description 2
• 208000027496 Behcet disease Diseases 0.000 claims description 2
• 208000010392 Bone Fractures Diseases 0.000 claims description 2
• 206010006811 Bursitis Diseases 0.000 claims description 2
• 241000222122 Candida albicans Species 0.000 claims description 2
• 206010007134 Candida infections Diseases 0.000 claims description 2
• 206010064012 Central pain syndrome Diseases 0.000 claims description 2
• 208000018380 Chemical injury Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 2
• 206010010741 Conjunctivitis Diseases 0.000 claims description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
• 206010013886 Dysaesthesia Diseases 0.000 claims description 2
• 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
• 108010008165 Etanercept Proteins 0.000 claims description 2
• 208000001640 Fibromyalgia Diseases 0.000 claims description 2
• 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
• 208000009889 Herpes Simplex Diseases 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 208000035154 Hyperesthesia Diseases 0.000 claims description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
• 206010022773 Intracranial pressure increased Diseases 0.000 claims description 2
• 208000000913 Kidney Calculi Diseases 0.000 claims description 2
• 208000002720 Malnutrition Diseases 0.000 claims description 2
• 208000006670 Multiple fractures Diseases 0.000 claims description 2
• 206010050031 Muscle strain Diseases 0.000 claims description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
• 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
• 206010029240 Neuritis Diseases 0.000 claims description 2
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 2
• 206010033078 Otitis media Diseases 0.000 claims description 2
• 208000004983 Phantom Limb Diseases 0.000 claims description 2
• 206010056238 Phantom pain Diseases 0.000 claims description 2
• 206010034960 Photophobia Diseases 0.000 claims description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
• 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
• 206010037660 Pyrexia Diseases 0.000 claims description 2
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 2
• 206010038910 Retinitis Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 208000008765 Sciatica Diseases 0.000 claims description 2
• 206010040744 Sinus headache Diseases 0.000 claims description 2
• 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
• 208000000491 Tendinopathy Diseases 0.000 claims description 2
• 206010043255 Tendonitis Diseases 0.000 claims description 2
• 206010043269 Tension headache Diseases 0.000 claims description 2
• 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
• 206010046914 Vaginal infection Diseases 0.000 claims description 2
• 201000008100 Vaginitis Diseases 0.000 claims description 2
• 208000036142 Viral infection Diseases 0.000 claims description 2
• 229960002964 adalimumab Drugs 0.000 claims description 2
• 206010053552 allodynia Diseases 0.000 claims description 2
• 229960000836 amitriptyline Drugs 0.000 claims description 2
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 2
• 230000003388 anti-hormonal effect Effects 0.000 claims description 2
• 229940125681 anticonvulsant agent Drugs 0.000 claims description 2
• 229940005513 antidepressants Drugs 0.000 claims description 2
• 208000010668 atopic eczema Diseases 0.000 claims description 2
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
• 201000003984 candidiasis Diseases 0.000 claims description 2
• 229960000623 carbamazepine Drugs 0.000 claims description 2
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
• 229960000590 celecoxib Drugs 0.000 claims description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
• 230000035606 childbirth Effects 0.000 claims description 2
• 210000002808 connective tissue Anatomy 0.000 claims description 2
• 238000001816 cooling Methods 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• 229960000403 etanercept Drugs 0.000 claims description 2
• 229960004945 etoricoxib Drugs 0.000 claims description 2
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims description 2
• 108020001507 fusion proteins Proteins 0.000 claims description 2
• 102000037865 fusion proteins Human genes 0.000 claims description 2
• 229960002870 gabapentin Drugs 0.000 claims description 2
• 206010017758 gastric cancer Diseases 0.000 claims description 2
• 208000010749 gastric carcinoma Diseases 0.000 claims description 2
• 201000005917 gastric ulcer Diseases 0.000 claims description 2
• 229960001680 ibuprofen Drugs 0.000 claims description 2
• 229960000905 indomethacin Drugs 0.000 claims description 2
• 238000007917 intracranial administration Methods 0.000 claims description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
• 229960000991 ketoprofen Drugs 0.000 claims description 2
• 229940043355 kinase inhibitor Drugs 0.000 claims description 2
• 229960001848 lamotrigine Drugs 0.000 claims description 2
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 2
• 238000009593 lumbar puncture Methods 0.000 claims description 2
• 201000001441 melanoma Diseases 0.000 claims description 2
• 208000037819 metastatic cancer Diseases 0.000 claims description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
• 206010027599 migraine Diseases 0.000 claims description 2
• 229960002009 naproxen Drugs 0.000 claims description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
• 229960001158 nortriptyline Drugs 0.000 claims description 2
• 235000018343 nutrient deficiency Nutrition 0.000 claims description 2
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 2
• 208000035824 paresthesia Diseases 0.000 claims description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
• 229960002702 piroxicam Drugs 0.000 claims description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
• 229960001233 pregabalin Drugs 0.000 claims description 2
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
• 208000005333 pulmonary edema Diseases 0.000 claims description 2
• 201000003068 rheumatic fever Diseases 0.000 claims description 2
• 229960000371 rofecoxib Drugs 0.000 claims description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
• 208000007056 sickle cell anemia Diseases 0.000 claims description 2
• 201000009890 sinusitis Diseases 0.000 claims description 2
• 208000020431 spinal cord injury Diseases 0.000 claims description 2
• 201000000498 stomach carcinoma Diseases 0.000 claims description 2
• 238000001356 surgical procedure Methods 0.000 claims description 2
• 201000004415 tendinitis Diseases 0.000 claims description 2
• 208000012720 thalamic disease Diseases 0.000 claims description 2
• 206010043778 thyroiditis Diseases 0.000 claims description 2
• 208000037816 tissue injury Diseases 0.000 claims description 2
• 239000003053 toxin Substances 0.000 claims description 2
• 231100000765 toxin Toxicity 0.000 claims description 2
• 108700012359 toxins Proteins 0.000 claims description 2
• 230000008736 traumatic injury Effects 0.000 claims description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
• 229960002004 valdecoxib Drugs 0.000 claims description 2
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 2
• 208000019553 vascular disease Diseases 0.000 claims description 2
• 230000009385 viral infection Effects 0.000 claims description 2
• 230000029663 wound healing Effects 0.000 claims description 2
• 208000000094 Chronic Pain Diseases 0.000 claims 1
• 102000048266 Nociceptin Human genes 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 description 23
• 108091022875 Microtubule Proteins 0.000 description 15
• 102000029749 Microtubule Human genes 0.000 description 15
• 210000004688 microtubule Anatomy 0.000 description 15
• 238000002360 preparation method Methods 0.000 description 14
• 230000005855 radiation Effects 0.000 description 14
• 239000000126 substance Substances 0.000 description 13
• 230000000694 effects Effects 0.000 description 12
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 12
• 239000000243 solution Substances 0.000 description 11
• 229930012538 Paclitaxel Natural products 0.000 description 10
• 229960001592 paclitaxel Drugs 0.000 description 10
• 102100026236 Interleukin-8 Human genes 0.000 description 9
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 9
• 102000002791 Interleukin-8B Receptors Human genes 0.000 description 9
• 230000007935 neutral effect Effects 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 108090001007 Interleukin-8 Proteins 0.000 description 7
• 210000004027 cell Anatomy 0.000 description 7
• 239000012535 impurity Substances 0.000 description 7
• 229940096397 interleukin-8 Drugs 0.000 description 7
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 108050006947 CXC Chemokine Proteins 0.000 description 6
• 102000019388 CXC chemokine Human genes 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 5
• 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
• 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 4
• 229940034982 antineoplastic agent Drugs 0.000 description 4
• 230000005784 autoimmunity Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 238000000227 grinding Methods 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000011278 mitosis Effects 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 102000009410 Chemokine receptor Human genes 0.000 description 3
• 108050000299 Chemokine receptor Proteins 0.000 description 3
• 206010029113 Neovascularisation Diseases 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000035605 chemotaxis Effects 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 238000001144 powder X-ray diffraction data Methods 0.000 description 3
• 208000002574 reactive arthritis Diseases 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• DLMYFMLKORXJPO-FQEVSTJZSA-N (2R)-2-amino-3-[(triphenylmethyl)thio]propanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SC[C@H](N)C(O)=O)C1=CC=CC=C1 DLMYFMLKORXJPO-FQEVSTJZSA-N 0.000 description 2
• 108060003345 Adrenergic Receptor Proteins 0.000 description 2
• 102000017910 Adrenergic receptor Human genes 0.000 description 2
• 206010003267 Arthritis reactive Diseases 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
• 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
• 102000001902 CC Chemokines Human genes 0.000 description 2
• 108010040471 CC Chemokines Proteins 0.000 description 2
• 208000001840 Dandruff Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
• 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
• 101100061856 Homo sapiens CXCL2 gene Proteins 0.000 description 2
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
• 108010018976 Interleukin-8A Receptors Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 102400001111 Nociceptin Human genes 0.000 description 2
• 208000025174 PANDAS Diseases 0.000 description 2
• 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 2
• 240000004718 Panda Species 0.000 description 2
• 235000016496 Panda oleosa Nutrition 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 230000036428 airway hyperreactivity Effects 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000005056 compaction Methods 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
• 108010045524 dolastatin 10 Proteins 0.000 description 2
• 229940088679 drug related substance Drugs 0.000 description 2
• 229960001842 estramustine Drugs 0.000 description 2
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• OWPCHSCAPHNHAV-QIPOKPRISA-N rhizoxin Chemical compound C/C([C@@H]([C@@H](C)[C@H]1OC(=O)[C@@H]2O[C@H]2C[C@@H]2C[C@@H](OC(=O)C2)[C@H](C)/C=C/[C@H]2O[C@]2(C)[C@@H](O)C1)OC)=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-QIPOKPRISA-N 0.000 description 2
• 150000003839 salts Chemical group 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 150000004579 taxol derivatives Chemical class 0.000 description 2
• 229960004964 temozolomide Drugs 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
• AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
• HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
• 206010033646 Acute and chronic pancreatitis Diseases 0.000 description 1
• NMKUAEKKJQYLHK-UHFFFAOYSA-N Allocolchicine Natural products CC(=O)NC1CCC2=CC(OC)=C(OC)C(OC)=C2C2=CC=C(C(=O)OC)C=C21 NMKUAEKKJQYLHK-UHFFFAOYSA-N 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 229910001369 Brass Inorganic materials 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
• 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
• 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
• 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
• 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
• 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
• OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• 101710139422 Eotaxin Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
• 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
• 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 208000005615 Interstitial Cystitis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930126263 Maytansine Natural products 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
• 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
• KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010033165 Ovarian failure Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 102100030304 Platelet factor 4 Human genes 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 240000002871 Tectona grandis Species 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 238000004164 analytical calibration Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000002927 anti-mitotic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940045695 antineooplastic colchicine derivative Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 239000010951 brass Substances 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
• 229960002559 chlorotrianisene Drugs 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
• 229950004683 drostanolone propionate Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
• 150000003883 epothilone derivatives Chemical class 0.000 description 1
• 229960002568 ethinylestradiol Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229960002899 hydroxyprogesterone Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000012750 in vivo screening Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229910021432 inorganic complex Inorganic materials 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 230000021995 interleukin-8 production Effects 0.000 description 1
• 102000010681 interleukin-8 receptors Human genes 0.000 description 1
• 108010038415 interleukin-8 receptors Proteins 0.000 description 1
• 201000006334 interstitial nephritis Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000002664 langerhans' cell Anatomy 0.000 description 1
• 108010069773 lens intrinsic protein MIP 28 Proteins 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 229960001614 levamisole Drugs 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• NMKUAEKKJQYLHK-KRWDZBQOSA-N methyl (7s)-7-acetamido-1,2,3-trimethoxy-6,7-dihydro-5h-dibenzo[5,3-b:1',2'-e][7]annulene-9-carboxylate Chemical compound CC(=O)N[C@H]1CCC2=CC(OC)=C(OC)C(OC)=C2C2=CC=C(C(=O)OC)C=C21 NMKUAEKKJQYLHK-KRWDZBQOSA-N 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 229960001566 methyltestosterone Drugs 0.000 description 1
• 239000010445 mica Substances 0.000 description 1
• 229910052618 mica group Inorganic materials 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
• XTSSXTWGEJTWBM-FQEVSTJZSA-N n-[(7s)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]benzamide Chemical compound N([C@H]1CCC=2C=C(C(=C(OC)C=2C2=CC=C(OC)C(=O)C=C21)OC)OC)C(=O)C1=CC=CC=C1 XTSSXTWGEJTWBM-FQEVSTJZSA-N 0.000 description 1
• CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 229950006344 nocodazole Drugs 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 239000003605 opacifier Substances 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 201000004535 ovarian dysfunction Diseases 0.000 description 1
• 231100000539 ovarian failure Toxicity 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 230000037048 polymerization activity Effects 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 235000020004 porter Nutrition 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
• DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000020347 spindle assembly Effects 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 230000002446 thrombocytic effect Effects 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
• 229950001353 tretamine Drugs 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 150000004654 triazenes Chemical class 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• 229960004982 vinblastine sulfate Drugs 0.000 description 1
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
• 229960002110 vincristine sulfate Drugs 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1